Verrica Pharmaceuticals Inc. Finance Lease, Liability, to be Paid, Year Three
Verrica Pharmaceuticals Inc. (VRCA) had Finance Lease, Liability, to be Paid, Year Three of $163.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Commitment and Contingencies › Finance Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree · last filed 2026-08-06
- 2026-06-30: Finance Lease, Liability, to be Paid, Year Three $163.00K.
- 2026-03-31: Finance Lease, Liability, to be Paid, Year Three $66.00K.
- 2025-12-31: Finance Lease, Liability, to be Paid, Year Three $211.00K.
- 2025-09-30: Finance Lease, Liability, to be Paid, Year Three $173.00K.
| Period end | Finance Lease, Liability, to be Paid, Year Three |
|---|---|
| 2026-06-30 | $163.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $66.00K 10-Q · filed 2026-05-12 |
| 2025-12-31 | $211.00K 10-K · filed 2026-03-11 |
| 2025-09-30 | $173.00K 10-Q · filed 2025-11-14 |
| 2025-06-30 | $133.00K 10-Q · filed 2025-08-12 |
| 2025-03-31 | $133.00K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $335.00K 10-K · filed 2025-03-11 |
| 2024-09-30 | $774.00K 10-Q · filed 2024-11-05 |
| 2024-06-30 | $643.00K 10-Q · filed 2024-08-14 |
| 2024-03-31 | $592.00K 10-Q · filed 2024-05-13 |
| 2023-12-31 | $343.00K 10-K · filed 2024-02-29 |
| 2023-09-30 | $27.00K 10-Q · filed 2023-11-09 |
| 2021-12-31 | $8.00K 10-K · filed 2022-03-02 |
| 2021-09-30 | $8.00K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $8.00K 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |